GENETIC ENGINEERING APPROACHES FOR MALARIA VACCINES

疟疾疫苗的基因工程方法

• 批准号: 3505981
• 负责人: PHILIP JEFFREYJ BARR
• 金额: $ 24.09万
• 依托单位: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-05-01 至 1990-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3505981
• 关键词: Plasmodium berghei; Plasmodium falciparum; Primates; erythrocytes; genetic manipulation; genetic recombination; immunological substance; laboratory mouse; laboratory rabbit; malaria; malaria vaccines; protozoal antigen; surface antigens; tissue /cell culture

The objective of this proposal is to use genetic engineering methodologies for the development of safe and effective subunit vaccines for preventing infection by human malarial parasites. Plasmodium falciparum and P. vivax, the most common forms of human malaria, are highly prevalent worldwide and cause considerable morbidity and mortality. An increase in drug resistance by the Plasmodia has emphasized the need for an effective immunoprohylaxis against this organism. Currently however, no vaccine for malaria exists. We plan to investigate the immunological properties of various parasite surface antigens produced in genetically engineered yeast. Similar expression systems are currently being used for the production of other vaccines (Hepatitis B Virus surface antigens) and also for enzymes and hormones for therapeutic use in humans. Purified recombinant proteins will be used for immunogenicity studies in rodents and sub-human primates with a view to their eventual clinical trial in humans. In addition, the availability of these recombinant antigens will contribute to our understanding of basic aspects of pathogenesis and fundamental mechanisms of immunity.

这项提案的目的是利用基因工程 开发安全有效的亚单位的方法 用于预防人疟疾寄生虫感染的疫苗。 恶性疟原虫和间日疟原虫是人类感染的最常见形式， 疟疾在世界范围内非常流行， 发病率和死亡率。 耐药性的增加， 疟原虫强调了有效的免疫预防的必要性 对抗这种生物 然而，目前还没有疟疾疫苗 存在. 我们计划研究 各种寄生虫表面抗原产生于基因 工程酵母 类似的表达系统目前正在 用于生产其他疫苗（B型肝炎病毒 表面抗原）以及用于治疗的酶和激素 用于人类。 纯化的重组蛋白将用于 啮齿类动物和亚人灵长类动物中的免疫原性研究 最终的临床试验。 此外该 这些重组抗原的可用性将有助于我们 对发病机理和基本原理的基本认识 免疫机制。